Equillium Inc

Equillium Inc. is a clinical-stage biotechnology company headquartered in San Diego, California. With 58 employees, the company focuses on developing innovative treatments for severe autoimmune and inflammatory diseases. Equillium's primary focus is itolizumab, a monoclonal antibody designed to restore immune system balance. Itolizumab targets the CD6-ALCAM signaling pathway, aiming to reduce inflammation associated with various diseases. Their pipeline currently targets acute graft-versus-host disease, lupus nephritis, and uncontrolled asthma. The company's mission is to significantly improve the lives of patients suffering from unmet medical needs in these disease areas. Equillium believes itolizumab's targeted approach holds promise as a best-in-class treatment for multiple severe immuno-inflammatory disorders. For more information, visit Equillium's website at equilliumbio.com.